In November 2018, the FDA issued a recall of Losartan after detecting trace amounts of the probable human carcinogen N-nitrosodiethylamine (NDEA). This is the third blood pressure drug to have been recalled due to possible cancer risk.
Many patients that were on Valsartan were switched over to Losartan after Valsartan was recalled in July 2018. However, these Losartan users are still at risk for contamination. Did you or a loved one contract cancer after taking a “Sartan” blood pressure medication drug? Contact our experienced drug recall law office for a free consultation.